Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?
Kupersmith
Mark J
MJ
D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009157:Myasthenia Gravis / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use*; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000276:immunology
D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D011729:Pyridostigmine Bromide; D011241:Prednisone